modelCapsaicin
Extends from Pharmacolibrary.Drugs.ATC.M.M02AB01.
Information
| name: | Capsaicin | |
| ATC code: | M02AB01 | route: | topical |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 440 | L |
| clearance: | 40 | L/h |
| other parameters in model implementation | ||
Capsaicin is a naturally occurring compound derived from chili peppers, primarily used as a topical analgesic for the treatment of neuropathic pain, musculoskeletal pain, and arthritis. It acts by desensitizing sensory neurons and is commonly available in creams or patches. Capsaicin is approved for topical use in several regions, including the USA and EU.
Pharmacokinetics
Pharmacokinetic parameters estimated for topical administration in healthy adults; detailed PK data in humans are limited. Most data are from animal or in vitro studies.
References
Babbar, S, et al., & Bley, K (2009). Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Therapeutic drug monitoring 31(4) 502–510. DOI:10.1097/FTD.0b013e3181a8b200 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19494795
Kalliomäki, J, et al., & Simpson, DM (2013). Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. Scandinavian journal of pain 4(2) 77–83. DOI:10.1016/j.sjpain.2012.10.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29913894
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)